Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 27;2(2):CD011417.
doi: 10.1002/14651858.CD011417.pub2.

Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions

Smita Akkinapally  1 , Shilpa G Hundalani, Madhulika Kulkarni, Caraciolo J Fernandes, Antonio G Cabrera, Binoy Shivanna, Mohan Pammi
Affiliations

Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions

Smita Akkinapally et al. Cochrane Database Syst Rev. .

Abstract

Background: Prostaglandin E1 (PGE1) is used to keep the ductus arteriosus patent and can be life-saving in neonates with ductal-dependent cardiac lesions. PGE1 is used to promote mixing of pulmonary and systemic blood flow or improve pulmonary or systemic circulations, prior to balloon atrial septostomy or surgery. PGE1 therapy may cause several short-term and long-term adverse effects. The efficacy and safety of PGE1 in neonates with ductal-dependent cardiac lesions has not been systematically reviewed.

Objectives: To determine the efficacy and safety of both short-term (< 120 hours) and long-term (≥120 hours) PGE1 therapy in maintaining patency of the ductus arteriosus and decreasing mortality in ductal-dependent cardiac lesions.

Search methods: We searched the literature in October 2017, using the search strategy recommended by Cochrane Neonatal. We searched electronic databases (CENTRAL (in the Cochrane Library), MEDLINE, CINAHL, Embase); abstracts of the Pediatric Academic Societies; websites for registered trials at www.clinicaltrials.gov and www.controlled-trials.com; and in the reference list of identified articles.

Selection criteria: Randomized or quasi-randomized trials using PGE1 at any dose or duration to maintain ductal patency in term or late preterm (≥ 34 weeks' gestation) infants with ductal-dependent cardiac lesions and which reported effectiveness and safety in the short term or long term.

Data collection and analysis: We followed the standard Cochrane methods for conducting a systematic review. Two review authors (SA and MP) independently assessed the titles and abstracts of studies identified by the search strategy to determine eligibility for inclusion. We obtained the full-text version if eligibility could not be done reliably by title and abstract. We resolved any differences by discussion. We designed electronic forms for trial inclusion/exclusion, data extraction, and for requesting additional published information from authors of the original reports.

Main results: Our search did not identify any completed or ongoing trials that met our inclusion criteria.

Authors' conclusions: There is insufficient evidence from randomized controlled trials to determine the safety and efficacy of PGE1 in neonates with ductal-dependent cardiac lesions. Evidence from observational trials have informed clinical practice on the use of PGE, which is now considered the standard of care for ductal-dependent cardiac lesions. It is unlikely that randomized controlled studies will be performed for this indication but comparative efficacy of newer formulations of PGE1, different doses of PGE1 and studies comparing PGE with PDA stents or other measures to keep the ductus open may be ethical and necessary.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest to declare for any author.

Update of

  • doi: 10.1002/14651858.CD011417

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies excluded from this review

Atik 1989 {published data only}
    1. Atik E, Arango Gutierrez J, Lyra Filho FJC, Iwahashi ER, Ribeiro IG, Tenorio de Albuquerque AM, et al. Infusion of prostaglandin E1 in ductus dependent congenital heart disease. Report of 47 cases [Infusao de prostaglandina E1 em cariopatias congenitas canal‐dependentes. Analise de 47 casos]. Arquivos Brasileiros de Cardiologia 1989;53(2):93‐7. - PubMed
Babyn 1995 {published data only}
    1. Babyn P, Peled N, Manson D, Dagan O, Silver MM, Koren G. Radiologic features of gastric outlet obstruction in infants after long‐term prostaglandin administration. Pediatric Radiology 1995;25(1):41‐3. [PUBMED: 7761161] - PubMed
Hallidie‐Smith 1984 {published data only}
    1. Hallidie‐Smith KA. Prostaglandin E1 in suspected ductus dependent cardiac malformation. Archives of Disease in Childhood 1984;59(11):1020‐6. [PUBMED: 6542338] - PMC - PubMed
Ohara 1985 {published data only}
    1. Ohara T, Ogata H, Fujiyama JI, Murata Y, Abe JI, Kakuta K, et al. Effects of Prostaglandin E‐1 Infusion in the pre‐operative management of critical congenital heart disease. Tohoku Journal of Experimental Medicine 1985;146(2):237‐49. [PUBMED: 4040664] - PubMed
Ono 1980 {published data only}
    1. Ono Y, Yamada O, Arakaki Y. Favorable and adverse effects of prostaglandin E1 in infants with ductus dependent congenital heart disease. Annales Paediatrici Japonici 1980;26(4):1‐6; 38.
Saxena 1998 {published data only}
    1. Saxena A, Sharma M, Kothari SS, Juneja R, Reddy SC, Sharma R, et al. Prostaglandin E1 in infants with congenital heart disease: Indian experience. Indian Pediatrics 1998;35(11):1063‐9. [PUBMED: 10216540] - PubMed

Additional references

Barst 1989
    1. Barst RJ, Gersony WM. The pharmacologic treatment of patent ductus arteriosus: a review of the evidence. Drugs 1989;38(2):249‐66. - PubMed
Benson 1979
    1. Benson LN, Olley PM, Patel RG, Coceani F, Rowe RD. Role of prostaglandin E1 infusion in the management of transposition of the great arteries. American Journal of Cardiology 1979;44(4):691‐6. [PUBMED: 484498] - PubMed
Bouayad 2001
    1. Bouayad A, Kajino H, Waleh N, Fouron JC, Andelfinger G, Varma DR, et al. Characterization of PGE2 receptors in fetal and newborn lamb ductus arteriosus. American Journal of Physiology. Heart and Circulatory Physiology 2001;280(5):H2342‐9. [PUBMED: 11299240] - PubMed
Brodlie 2008
    1. Brodlie M, Chaudhari M, Hasan A. Prostaglandin therapy for ductal patency: how long is too long?. Acta Paediatrica 2008;97(9):1303‐4. [DOI: 10.1111/j.1651-2227.2008.00872.x; PUBMED: 18492129] - DOI - PubMed
Buck 1991
    1. Buck ML. Prostaglandin E1 treatment of congenital heart disease: use prior to neonatal transport. DICP : the Annals of Pharmacotherapy 1991;25(4):408‐9. [PUBMED: 1926911] - PubMed
Calder 1984
    1. Calder AL, Kirker JA, Neutze JM, Starling MB. Pathology of the ductus arteriosus treated with prostaglandins: comparisons with untreated cases. Pediatric Cardiology 1984;5(2):85‐92. [DOI: 10.1007/BF02424956; PUBMED: 6591146] - DOI - PubMed
Estes 2007
    1. Estes K, Nowicki M, Bishop P. Cortical hyperostosis secondary to prostaglandin E1 therapy. Journal of Pediatrics 2007;151(4):441. [DOI: 10.1016/j.jpeds.2007.02.066; PUBMED: 17889087] - DOI - PubMed
Faye‐Peterson 1996
    1. Faye‐Petersen OM, Johnson WH Jr, Carlo WA, Hedlund GL, Pacifico AD, Blair HC. Prostaglandin E1‐induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanisms. Pediatric Pathology & Laboratory Medicine 1996;16(3):489‐507. [PUBMED: 9025848] - PubMed
Freed 1981
    1. Freed MD, Heymann MA, Lewis AB, Roehl SL, Kensey RC. Prostaglandin E1 infants with ductus arteriosus‐dependent congenital heart disease. Circulation 1981;64(5):899‐905. [PUBMED: 7285305] - PubMed
Gittenberger‐de Groot 1978
    1. Gittenberger‐de Groot AC, Moulaert AJ, Harinck E, Becker AE. Histopathology of the ductus arteriosus after prostaglandin E1 administration in ductus dependent cardiac anomalies. British Heart Journal 1978;40(3):215‐20. [PUBMED: 637973] - PMC - PubMed
Graham 1978a
    1. Graham TP, Atwood GF, Boucek RJ. Use of prostaglandin E1 for emergency palliation of symptomatic coarctation of the aorta. Catheterization and Cardiovascular Diagnosis 1978;4(1):97‐102. [PUBMED: 77192] - PubMed
Graham 1978b
    1. Graham TP, Atwood GF, Boucek RJ Jr. Pharmacologic dilatation of the ductus arteriosus with prostaglandin E1 in infants with congenital heart disease. Southern Medical Journal 1978;71(10):1238‐41. [PUBMED: 81528] - PubMed
Heymann 1977
    1. Heymann MA, Rudolph AM. Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia. Pediatrics 1977;59(3):325‐9. [PUBMED: 840551] - PubMed
Heymann 1979
    1. Heymann MA, Berman W Jr, Rudolph AM, Whitman V. Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities. Circulation 1979;59(1):169‐73. [PUBMED: 758109] - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Host 1988
    1. Host A, Halken S, Andersen PE Jr. Reversibility of cortical hyperostosis following long‐term prostaglandin E1 therapy in infants with ductus‐dependent congenital heart disease. Pediatric Radiology 1988;18(2):149‐53. [PUBMED: 3281113] - PubMed
Huang 2013
    1. Huang FK, Lin CC, Huang TC, Weng KP, Liu PY, Chen YY, et al. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus‐dependent pulmonary circulation. Pediatrics and Neonatology 2013;54(2):102‐6. [DOI: 10.1016/j.pedneo.2012.10.007; PUBMED: 23590954] - DOI - PubMed
Kalloghlian 1996
    1. Kalloghlian AK, Frayha HH, deMoor MM. Cortical hyperostosis simulating osteomyelitis after short‐term prostaglandin E1 infusion. European Journal of Pediatrics 1996;155(3):173‐4. [PUBMED: 8929722] - PubMed
Kobayashi 2002
    1. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins & Other Lipid Mediators 2002;68‐69:557‐73. [PUBMED: 12432943] - PubMed
Lacher 2007
    1. Lacher M, Schneider K, Dalla Pozza R, Schweinitz DV. Gastric outlet obstruction after long‐term prostaglandin administration mimicking hypertrophic pyloric stenosis. European Journal of Pediatric Surgery 2007;17(5):362‐4. [DOI: 10.1055/s-2007-965422; PUBMED: 17968795] - DOI - PubMed
Lang 1979
    1. Lang P, Freed MD, Bierman FZ, Norwood WI Jr, Nadas AS. Use of prostaglandin E1 in infants with d‐transposition of the great arteries and intact ventricular septum. American Journal of Cardiology 1979;44(1):76‐81. [PUBMED: 88172] - PubMed
Leonhardt 2003
    1. Leonhardt A, Glaser A, Wegmann M, Schranz D, Seyberth H, Nüsing R. Expression of prostanoid receptors in human ductus arteriosus. British Journal of Pharmacology 2003;138(4):655‐9. [DOI: 10.1038/sj.bjp.0705092; PUBMED: 12598419] - DOI - PMC - PubMed
Leoni 1984
    1. Leoni F, Huhta JC, Douglas J, MacKay R, de Leval MR, Macartney FJ, et al. Effect of prostaglandin on early surgical mortality in obstructive lesions of the systemic circulation. British Heart Journal 1984;52(6):654‐9. [PUBMED: 6542422] - PMC - PubMed
Lewis 1978
    1. Lewis AB, Takahashi M, Lurie PR. Administration of prostaglandin E1 in neonates with critical congenital cardiac defects. Journal of Pediatrics 1978;93(3):481‐5. [PUBMED: 690772] - PubMed
Lewis 1981
    1. Lewis AB, Freed MD, Heymann MA, Roehl SL, Kensey RC. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease. Circulation 1981;64(5):893‐8. [PUBMED: 7285304] - PubMed
Marino 2001
    1. Marino BS, Bird GL, Wernovsky G. Diagnosis and management of the newborn with suspected congenital heart disease. Clinics in Perinatology 2001;28(1):91‐136. [PUBMED: 11265513] - PubMed
Meckler 2009
    1. Meckler GD, Lowe C. To intubate or not to intubate? Transporting infants on prostaglandin E1. Pediatrics 2009;123(1):e25‐30. [DOI: 10.1542/peds.2008-0641; PUBMED: 19064611] - DOI - PubMed
Miller 2004
    1. Miller SF. Resolution of calcific brown fat necrosis associated with prostaglandin therapy for cyanotic congenital heart disease in neonates: report of two cases. Pediatric Radiology 2004;34(11):919‐23. [DOI: 10.1007/s00247-004-1231-7; PUBMED: 15185042] - DOI - PubMed
Momma 1980
    1. Momma K, Uemura S, Nishihara S, Ota Y. Dilatation of the ductus arteriosus by prostaglandins and prostaglandin's precursors. Pediatric Research 1980;14(9):1074‐7. [DOI: 10.1203/00006450-198009000-00011; PUBMED: 7192845] - DOI - PubMed
Momma 1996
    1. Momma K. Lipo‐PGE1 treatment of the neonate with critical congenital heart disease and ductus‐arteriosus dependent circulation. Advanced Drug Delivery Reviews 1996;20(2‐3):177‐80.
Momma 2005
    1. Momma K, Toyoshima K, Takeuchi D, Imamura S, Nakanishi T. In vivo reopening of the neonatal ductus arteriosus by a prostanoid EP4‐receptor agonist in the rat. Prostaglandins & Other Lipid Mediators 2005;78(1‐4):117‐28. [DOI: 10.1016/j.prostaglandins.2005.04.006; PUBMED: 16303610] - DOI - PubMed
Nadroo 2000
    1. Nadroo AM, Shringari S, Garg M, al‐Sowailem AM. Prostaglandin induced cortical hyperostosis in neonates with cyanotic heart disease. Journal of Perinatal Medicine 2000;28(6):447‐52. [DOI: 10.1515/JPM.2000.060; PUBMED: 11155430] - DOI - PubMed
Neutze 1977
    1. Neutze JM, Starling MB, Elliott RB, Barratt‐Boyes BG. Palliation of cyanotic congenital heart disease in infancy with E‐type prostaglandins. Circulation 1977;55(2):238‐41. [PUBMED: 64317] - PubMed
Olley 1976
    1. Olley PM, Coceani F, Bodach E. E‐type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. Circulation 1976;53(4):728‐31. [PUBMED: 56243] - PubMed
Peled 1992
    1. Peled N, Dagan O, Babyn P, Silver MM, Barker G, Hellmann J, et al. Gastric‐outlet obstruction induced by prostaglandin therapy in neonates. New England Journal of Medicine 1992;327(8):505‐10. [DOI: 10.1056/NEJM199208203270801; PUBMED: 1635565] - DOI - PubMed
Penny 2001
    1. Penny DJ, Shekerdemian LS. Management of the neonate with symptomatic congenital heart disease. Archives of Disease in Childhood. Fetal and Neonatal Edition 2001;84(3):F141‐5. [PUBMED: 11320036] - PMC - PubMed
Perme 2013
    1. Perme T, Mali S, Vidmar I, Gvardijančič D, Blumauer R, Mishaly D, et al. Prolonged prostaglandin E1 therapy in a neonate with pulmonary atresia and ventricular septal defect and the development of antral foveolar hyperplasia and hypertrophic pyloric stenosis. Upsala Journal of Medical Sciences 2013;118(2):138‐42. [DOI: 10.3109/03009734.2013.778374; PUBMED: 23521358] - DOI - PMC - PubMed
Persigehl 1984
    1. Persigehl M, Hövels‐Gürich H, Bernuth G. Skeletal side effects of treatment with prostaglandin E1 [Nebenwirkungen am skelettsystem bei behandlung mit prostaglandin E]. RoFo 1984;141(4):427‐30. [DOI: 10.1055/s-2008-1053163; PUBMED: 6436918] - DOI - PubMed
Raboi 1999
    1. Raboi CA, Smith W. Brown fat necrosis in the setting of congenital heart disease and prostaglandin E1 use: a case report. Pediatric Radiology 1999;29(1):61‐3. [DOI: 10.1007/s002470050536; PUBMED: 9880620] - DOI - PubMed
Ramstad 2005
    1. Ramstad T, Hadden CE, Martin GE, Speaker SM, Teagarden DL, Thamann TJ. Determination by NMR of the binding constant for the molecular complex between alprostadil and alpha‐cyclodextrin. Implications for a freeze‐dried formulation. International Journal of Pharmaceutics 2005;296(1‐2):55‐63. [PUBMED: PMID: 15885455] - PubMed
Reese 2010
    1. Reese J, Veldman A, Shah L, Vucovich M, Cotton RB. Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period. Seminars in Perinatology 2010;34(3):222‐30. [DOI: 10.1053/j.semperi.2010.02.007; PUBMED: 20494739] - DOI - PMC - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ringel 1982
    1. Ringel RE, Brenner JI, Haney PJ, Burns JE, Moulton AL, Berman MA. Prostaglandin‐induced periostitis: a complication of long‐term PGE1 infusion in an infant with congenital heart disease. Radiology 1982;142(3):657‐8. [DOI: 10.1148/radiology.142.3.7199748; PUBMED: 7199748] - DOI - PubMed
Roehl 1982
    1. Roehl SL, Townsend RJ. Alprostadil (Prostin VR Pediatric Sterile Solution, The Upjohn Company). Drug Intelligence & Clinical Pharmacy 1982;16(11):823‐32. [PUBMED: 6756848] - PubMed
Saji 1991
    1. Saji T, Matsuura H, Hoshino K, Yamamoto S, Ishikita T, Matsuo N. Oral prostaglandin E1 derivative (OP‐1206) in an infant with double outlet right ventricle and pulmonary stenosis. Effect on ductus‐dependent pulmonary circulation. Japanese Heart Journal 1991;32(5):735‐40. [PUBMED: 1774835] - PubMed
Shivananda 2010
    1. Shivananda S, Kirsh J, Whyte HE, Muthalally K, McNamara PJ. Accuracy of clinical diagnosis and decision to commence intravenous prostaglandin E1 in neonates presenting with hypoxemia in a transport setting. Journal of Critical Care 2010;25(1):174.e1‐9. [DOI: 10.1016/j.jcrc.2009.04.005; PUBMED: 19577418] - DOI - PubMed
Silove 1985
    1. Silove ED, Roberts DG, Giovanni JV. Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease. Archives of Disease in Childhood 1985;60(11):1025‐30. [PUBMED: 3865636] - PMC - PubMed
Smith 1995
    1. Smith GC, McGrath JC. Contractile effects of prostanoids on fetal rabbit ductus arteriosus. Journal of Cardiovascular Pharmacology 1995;25(1):113‐8. [PUBMED: 7723339] - PubMed
Smith 1998
    1. Smith G. The pharmacology of the ductus arteriosus. Pharmacological Reviews 1998;50(1):35‐58. [PUBMED: 9549757] - PubMed
Smith 2001
    1. Smith GC, Wu WX, Nijland MJ, Koenen SV, Nathanielsz PW. Effect of gestational age, corticosteroids, and birth on expression of prostanoid EP receptor genes in lamb and baboon ductus arteriosus. Journal of Cardiovascular Pharmacology 2001;37(6):697‐704. [PUBMED: 11392466] - PubMed
Takeda 2000
    1. Takeda N, Hiraishi S, Misawa H, Agata Y, Horiguchi Y, Fujino N, et al. Echocardiographic evaluation of the ductal morphology in patients with refractoriness to lipo‐prostaglandin E1 therapy. Pediatrics International 2000;42(2):134‐8. [PUBMED: 10804727] - PubMed
Teixeira 1984
    1. Teixeira OH, Carpenter B, MacMurray SB, Vlad P. Long‐term prostaglandin E1 therapy in congenital heart defects. Journal of the American College of Cardiology 1984;3(3):838‐43. [PUBMED: 6537955] - PubMed
Woo 1994
    1. Woo K, Emery J, Peabody J. Cortical hyperostosis: a complication of prolonged prostaglandin infusion in infants awaiting cardiac transplantation. Pediatrics 1994;93(3):417‐20. [PUBMED: 8115200] - PubMed

Publication types

MeSH terms

LinkOut - more resources